NRG Oncology has named the Barbara Ann Karmanos Cancer Institute and Wayne State University among the “Top 10 Accruing Lead Academic Participating Sites” for oncology trials. In January, the organization announced the leading sites at its annual Winter Meeting in Phoenix, Arizona.
Being acknowledged on this list means that Karmanos enrolled a high number of participants in therapeutic clinical trials between Jan. 1 and December 31, 2024. The clinical trials are National Clinical Trial Network (NCTN) and National Cancer Institute Community Oncology Research Program (NCORP) trials credited to NRG Oncology.
“Being on the forefront of establishing new ways to treat our patients more safely and effectively through clinical trials has the potential to directly impact quality of life and cancer outcomes,” said Michael Dominello, D.O., radiation oncologist, leader of the Neuro-Oncology Multidisciplinary Team (MDT), member of the Breast Cancer MDT, and principal investigator at Karmanos as an NRG Lead Academic Participation Site. “Making these trials available at Karmanos gives our patients therapy options not offered at non-NRG participating sites. With the collective data from national and international accrual on these studies, we will better understand how new treatment strategies may provide improvement over current standard-of-care options.”
To maintain their status, Lead Academic Participation Sites must meet rigorous requirements, such as providing timely high-quality data on trial performance, meeting enrollment requirements in either NCTN or NRG Oncology foundation trials, and receiving and maintaining data from NRG affiliate members.
NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve cancer patients' lives.
To learn more about radiation oncology treatment options offered at Karmanos, click here.